Skip to main content

Supply Issues Medline Sterile Surgical Gowns and Drapes (ICN 3223)

Important Customer Notice Status Update Type Supply Disruption

Ref: 2026/3223 ICN Number: 3223

Situation overview

  • Medline Industries has issued a Field Safety Notice for specific lots of sterile surgical drapes and sterile surgical gowns.
  • Medline determined that one of its suppliers did not adequately document calibrations for sealing equipment and sterilisation-related sensors.
  • As a precautionary measure, affected stock from this factory is being recalled and production at the impacted site has been temporarily suspended.
  • Medline operates a multi‑site manufacturing model. Only one manufacturing facility is impacted, and other approved facilities are continuing to produce the affected product lines.
  • As a result, production of these items is continuing but at constrained capacity while Medline rebalances supply across its network.
  • This issue impacts Medline’s global markets.

NHS Supply Chain response to Medline supply disruption issues

  • NHS Supply Chain is engaging regularly with Medline and the alternative suppliers in this market to be clear on stock availability.
  • As demand is likely to switch to alternative suppliers, we have taken a pro-active approach to protect stock levels for the benefit of the whole NHS by also applying Protect Demand Management to their products.
  • Protect Demand Management will be reviewed and amended once stock availability is fully known.
  • See our Downloads ▼ section to access the product listing for further information on the affected product codes and potential alternatives. The alternatives will be updated once we have reviewed the stock availability and made the related changes to our catalogue.
  • This ICN will be updated regularly.
  • See our Useful Links section to read the full Field Safety Notice (ICN 3221) which relates to this ICN.

  • We remain in regular discussions with Medline and alternative suppliers about their stock availability, with a focus on bringing the maximum number of products back into stock as quickly as possible.
  • The product listing has been updated and provides guidance on lines with good availability, as well as how to identify suitable alternatives that can support supply temporarily.
  • We continue to ask partners to order from the Available Stock tab on the product listing where possible and consider the guidance provided.
  • Some codes have now fully recovered, and further improvements are expected as inbound stock builds. Some items will remain subject to Protect Demand Management while we rebuild resilience levels.
  • Please be advised that to maintain continuity of supply for trusts, we have identified a further 49 indirect alternatives.
  • See our Downloadssection to view the additional Drape Alternatives tab on the product listing for further information.
  • Since the last update 59 products have now been removed from Protect Demand Management and are now available to order without restrictions.
  • 46 products remain suspended.
  • 22 products remain intermittent supply.
  • 78 products remain subject to Protect Demand Management.
  • We will continue to review all suspended lines regularly with Medline. As soon as stock becomes available, we will lift suspensions and update this ICN.
  • See our Downloadssection for the product listing showing all product codes subject to Protect Demand Management, along with guidance on alternative options.
  • The supply issue is still anticipated to be resolved by 15 May 2026.

Download our publications ▼

  • 3223 Medline Product Listing with Alternatives 23 February 2026

    An Excel file showing the product listing with alternatives for ICN 3223.
    Login to view the downloads
  • 3223 Medline Demand Capture Form

    An Excel file containing a demand capture form for if a product required is Protect Demand Managed and not been ordered previously.
  • 3223 Medline Demand Management Escalation Form

    A Word file containing an Escalation Form to be completed when either additional one-off product or a review of daily threshold allocation is required.